High dose chemotherapy with autologous stem cell transplant has improved survival for patients and is considered to be the single most powerful treatment in multiple myeloma today. However, myeloma typically relapses for most patients. Today's standard of care is for patients to collect their stem cells, receive high-dose melphalan and then be given back their previously collected cells. Siddartha Ganguly, MD, of the University of Kansas Medical Center is running a clinical trial to better understand: 1) how contaminated the stem cell collection sample is with myeloma cells, 2) if the myeloma in the collected stem cells can be killed using a proteasome inhibitor in the lab before they are given back to the patient, and 3) if cleaning up the stem cells makes a difference in progression-free survival for patients.
To learn more, click the link below to find the clinical trial on SparkCures. Stem Cell Collection and Bortezomib Clinical Trial
about the author
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.